Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Sharck Soup -- Ignore unavailable to you. Want to Upgrade?

To: Jim Spitz who wrote (37537)	1/15/2002 8:17:18 AM
From: Jim Spitz	Read Replies (1) \| Respond to of 37746

Lilly moving on after losing Prozac patent appeal Published Jan 15 2002 INDIANAPOLIS -- After fighting for six years to maintain its patent on Prozac, Eli Lilly and Co. reached the end of the legal road Monday when the U.S. Supreme Court refused to consider reinstating the drugmaker's rights to the popular antidepressant. Company officials said they were disappointed but not surprised. Generic versions of Prozac went on the market last year, shortly after a federal appeals court invalidated Lilly's patent. That patent would have protected the company's monopoly until December 2003 and brought in an estimated $4 billion in sales. Lilly sued generic-drug manufacturers for patent infringement in 1996, when they sought Food and Drug Administration approval to make a generic form of Prozac. Barr Laboratories Inc. and other generic drugmakers claimed Lilly had improperly double-patented Prozac to extend its exclusive control over the drug. The appeals court agreed. The Supreme Court did not comment in rejecting Lilly's appeal of that ruling. -- Associated Press © Copyright 2002 Star Tribune. All rights reserved.